



Vita Life Sciences Limited

ACN 003 190 421

ABN 35 003 190 421

Corporate Office

1/102 Bath Road,
Kirrawee NSW 2232

P.O. Box 3143

Kirrawee NSW 2232

T/Free: 1800 852 222

T: 02 9545 2633

F: 02 9545 1311

vitalifesciences.com

26 June 2023

Market Announcements
Australian Securities Exchange Ltd
20 Bridge Street
Sydney, NSW 2000

GUIDANCE

Vita Life Sciences (ASX: VLS) announces the following guidance for the half year ending 30 June 2023 (H1 2023):

Sales: \$33.0m-\$33.5m (H1 2022: \$32.7m)

Pre-tax Profit: \$4.7m-5.0m (H1 2022: \$5.3m)

The Australian domestic business and exports to China are forecast to contribute positively to Group sales growth. Other Asian markets performed well in challenging market conditions.

A slight shift in product mix impacting margins, higher advertising and trade-related expenses aligned to sales are forecast to reduce pre-tax profit slightly when compared to the PCP.

Directors remain confident to execute its current strategy to drive long term sustainable sales and profit growth.

This announcement has been authorised by the Board of Directors.

Andrew O'Keefe
Managing Director

Email: enquiries@vitalifesciences.com.au

